Business
Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership.
About this update from Kelyniam Global, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership\r\n \r\n \r\n\r\n\r\nKelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nCANTON, Conn., May 12, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the first quarter ended March 31, 2025, and highlighted a new partnership to drive future growth.\r\n\r\nQ1 2025 Financial Highlights (compared to Q1 2024):\r\n\r\n Total revenue of $624,910, compared to $957,447, a decrease of 34.7%.\r\n Gross margin of $470,940, compared to $743,719, a decrease of 36.6%.\r\n Operating loss of $(140,556), compared to an operating profit of $123,599.\r\n \r\n \"Kelyniam experienced a challenging first quarter due to seasonal variability and the timing of surgical schedules, which delayed revenue recognition,\" said Ross Bjella, CEO of Kelyniam. \"To address these challenges, we strengthened our sales organization by appointing Alex Rivero as National Sales Director and plan to onboard up to 10 additional distributors in 2025. Our commitment to delivering custom implants within 24-48 hours, combined with strategic partnerships, positions us for improved performance.\"\r\nStrategic Partnerships: Kelyniam has entered a three-year distribution agreement with Osteopore Ltd. (ASX: OSX), a Singapore-based medical technology company specializing in regenerative implants. This agreement enables Kelyniam to distribute Osteopore's bioresorbable products, including Osteostrip®, Osteoplug®, and Osteomesh®, in the U.S., providing surgeons with advanced solutions for cranial bone regeneration.\r\n\"Our partnerships with Osteopore and Finceramica position Kelyniam as a leader in regenerative medicine in the U.S.,\" added Bjella. \"Regenerative products are an important part of the future of cranial surgery and will uniquely position Kelyniam in the market along with our commitment to quality and rapid service.\"\r\nDesiree Webb, Kelyniam's Chief Operating and Revenue Officer said, \"Osteopore's products are exceptional additions for surgeons in need of a biomimetic and bioresorbable option for areas where natural, healthy bone growth are desired. Kelyniam is laser focused on providing the...